{"id":688540,"date":"2022-09-23T16:24:30","date_gmt":"2022-09-23T20:24:30","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/"},"modified":"2022-09-23T16:24:30","modified_gmt":"2022-09-23T20:24:30","slug":"spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/","title":{"rendered":"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Sept.  23, 2022  (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IoVBayCIO99Fenxiu0uru7ONUQnWEQm6EybvU3KAlEmabNl1iKCMZ8f_DaL3_KSQpLVRGC_V7OHqwQS2wqSqSL6uiXaGTh8oP9s9tpLfY1qJoeM3-W2ziN1Vw2zpOw4JuSPmwPpmFPx83Ix8OhFnZ0urCb7_0qyVclJC8lZQark=\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.kaplanfox.com<\/u><\/a>) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (\u201cSpectrum\u201d or the \u201cCompany\u201d) (NASDAQ: SPPI) securities.<\/p>\n<p align=\"justify\">\n        <strong>If you purchased Spectrum securities and would like to discuss our investigation, please contact us by emailing <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sVgBb2KxnSPUQNt9PVUqWGUtpO3-zEMg8pVZoYg8XUnq29Gwh2JkHxp1VjvrTRuYRrfFyGHns3xv-RlD9Ixf0wTAUVqBxgAS9YJ7Bee12wc=\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <strong><br \/>\n            <u>jcampisi@kaplanfox.com<\/u><br \/>\n          <\/strong><br \/>\n        <\/a><br \/>\n        <strong> or by calling (212) 687-1980. <\/strong>\n      <\/p>\n<p align=\"justify\">On September 22, 2022, <em>Reuters<\/em> reported that advisers to the U.S Food and Drug Administration \u201cvoted against recommending Spectrum Pharmaceuticals\u2019\u00a0 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yT71r7yCC9gGStq9H6sH9PbvXwvZTe_CyRxihM1vwhnC3mXjjP21DaiSYZ37xMEyhuXYUTLhTVHfehAZHAiJO6vtpemJgMGfWU7U18Smvao=\" rel=\"nofollow noopener\" target=\"_blank\"><u>(SPPI.O)<\/u><\/a>\u00a0experimental drug for the treatment of patients with a form of non-small cell lung cancer. The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization. The panel&#8217;s decision was in-line with \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E9bgcqt1-PKoJRy_22-UfNwjPU9M8cf4JNYCnxwc5-22meH3oB7RKdBfUir923VcVdSENTYn0IV0rleT3n9rgdixBWf0CsGbCTUB7ne6ow0DBTyEmPT2gyk6GnHnSC5m\" rel=\"nofollow noopener\" target=\"_blank\"><u>briefing documents<\/u><\/a> released by the drug regulator on Tuesday that raised concerns over the efficacy of the treatment compared with existing drugs like Daiichi Sankyo\u2019s\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4CKqLDxYLuSEstP7vpDPQzIo2N7K9qQsCmxDuD4P7Y06BTfrfMO1pvYiQgWm63c_I7Fj5DJyONOU-OVZFaDi2jfp7CTkP_8yRqBbQLjdVzk=\" rel=\"nofollow noopener\" target=\"_blank\"><u>(4568.T)<\/u><\/a>\u00a0and AstraZeneca\u2019s Enhertu.\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FoTdX2oGnmrxsy68HN-OJt9cEwV2wdqY0hX7HZ7bqhIKi_NkqTJhgGD-IwNgs5P7-XoNSAV54GaaD8gqvsn_HYRvDOdrMRvJRULGEL_w6f3UIT_ebtecX6do34ZhhUNu-S7jLO5TMLb7vsP1Hdo3ULYrr4EtlzmfcuodG_hIg_fSR5phlgTcxi1bCYJjQMVR2hllB2rz7XB6pVF9uip60Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>read more<\/u><\/a>\u201d<\/p>\n<p align=\"start\">Following this news, Spectrum\u2019s stock price declined over 33% per share.<\/p>\n<p align=\"justify\">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.<\/p>\n<p align=\"justify\">\n        <strong>WHY CONTACT KAPLAN FOX &#8211; <\/strong>Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox &amp; Kilsheimer LLP, you may visit our website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IoVBayCIO99Fenxiu0uru8t-zBHwNb0tBclqfAtdZ8-NWE1BJIW4DhuqMtjxrHjxXK6ENnM-HTCiq5NQyJ6pgg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.kaplanfox.com<\/u><\/a>.<\/p>\n<p align=\"justify\">If you have any questions about this investigation, your rights, or your interests, please contact:<\/p>\n<p align=\"justify\">Jeffrey P. Campisi <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 850 Third Avenue, 14th Floor <br \/> New York, New York\u00a010022 <br \/> (212) 687-1980 <br \/> E-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sVgBb2KxnSPUQNt9PVUqWGUtpO3-zEMg8pVZoYg8XUlhZH2ZA-WSBbVjpzWWB9dOGXtK1E085UL1zp6a4bS9NdQoQij80Mtanl6VI-v-mRQ=\" rel=\"nofollow noopener\" target=\"_blank\"><u>jcampisi@kaplanfox.com<\/u><\/a><\/p>\n<p align=\"start\">Laurence D. King <br \/> KAPLAN FOX &amp; KILSHEIMER LLP <br \/> 1999 Harrison Street, Suite 1560 <br \/> Oakland, California 94612 <br \/> (415) 772-4704 <br \/> Fax:\u00a0 (415) 772-4707 <br \/> E-mail: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Tua4JFtpcCOq7zBQXFmz1Vl4RuoaTfe4HHemzWZoirCnayihp5g1SIjDyOG0Q8RuKPnbnvna6TIBuusnlsNeBgEKrZqMv4a_mmYsDGPjnRQ=\" rel=\"nofollow noopener\" target=\"_blank\"><u>lking@kaplanfox.com<\/u><\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTM3MDA5NjUtMzBhZi00NDRiLWJkNDctZmM3YzMwYTllZDMxLTEwMzE5OTk=\/tiny\/Kaplan-Fox-Kilsheimer-LLP.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (\u201cSpectrum\u201d or the \u201cCompany\u201d) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to discuss our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling (212) 687-1980. On September 22, 2022, Reuters reported that advisers to the U.S Food and Drug Administration \u201cvoted against recommending Spectrum Pharmaceuticals\u2019\u00a0 (SPPI.O)\u00a0experimental drug for the treatment of patients with a form of non-small cell lung cancer. The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization. The panel&#8217;s decision was in-line with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-688540","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (\u201cSpectrum\u201d or the \u201cCompany\u201d) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to discuss our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling (212) 687-1980. On September 22, 2022, Reuters reported that advisers to the U.S Food and Drug Administration \u201cvoted against recommending Spectrum Pharmaceuticals\u2019\u00a0 (SPPI.O)\u00a0experimental drug for the treatment of patients with a form of non-small cell lung cancer. The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization. The panel&#8217;s decision was in-line with &hellip; Continue reading &quot;Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-23T20:24:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud\",\"datePublished\":\"2022-09-23T20:24:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/\"},\"wordCount\":344,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/\",\"name\":\"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=\",\"datePublished\":\"2022-09-23T20:24:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/","og_locale":"en_US","og_type":"article","og_title":"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud - Market Newsdesk","og_description":"NEW YORK, Sept. 23, 2022 (GLOBE NEWSWIRE) &#8212; Kaplan Fox &amp; Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Spectrum Pharmaceuticals, Inc. (\u201cSpectrum\u201d or the \u201cCompany\u201d) (NASDAQ: SPPI) securities. If you purchased Spectrum securities and would like to discuss our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling (212) 687-1980. On September 22, 2022, Reuters reported that advisers to the U.S Food and Drug Administration \u201cvoted against recommending Spectrum Pharmaceuticals\u2019\u00a0 (SPPI.O)\u00a0experimental drug for the treatment of patients with a form of non-small cell lung cancer. The FDA panel voted 9 to 4 against the oral drug, poziotinib, citing marginal efficacy, high level of toxicities, and lack of dose optimization. The panel&#8217;s decision was in-line with &hellip; Continue reading \"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-23T20:24:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud","datePublished":"2022-09-23T20:24:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/"},"wordCount":344,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/","name":"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=","datePublished":"2022-09-23T20:24:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1MjU4OSM1MTY5NjU0IzIwMjA4OTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spectrum-pharmaceuticals-inc-nasdaq-sppi-investor-alert-kaplan-fox-investigates-potential-securities-fraud\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) Investor Alert: Kaplan Fox Investigates Potential Securities Fraud"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=688540"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/688540\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=688540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=688540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=688540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}